Overview

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Status:
Completed

Trial end date:
2020-06-30

Target enrollment:

Participant gender:

Summary

This study will randomized hematology oncology patients with active diarrhea and a NAAT positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo. The study is designed to include 30 patients (15 per arm). Outcomes will include C. difficile load using qPCR, VRE loads, structural and functional microbiome changes and frequency of bowel movements. All endpoints will be measured at several time points including days 0, 14, 21 and 90.

Phase:

Phase 2

Details

Lead Sponsor:

Medical College of Wisconsin

Collaborator:

The Jackson Laboratory for Genomic Medicine

Treatments:

Vancomycin